Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2012 | 01:16am CET

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
02/19NOVARTIS : Correction to Novartis CEO story
DJ
02/19Oncology Biosimilar Market to Grow at a High CAGR by 2025 - Top Players Inclu..
AQ
02/19Oncology Biosimilar Market to Grow at a High CAGR by 2025 – Top Players..
AQ
02/18NOVARTIS : CEO Steers Drug Maker Back to R&D
DJ
02/17NOVARTIS : New Data Show Cosentyx Improved Quality of Life Over 5 Years in Two T..
AQ
02/16NOVARTIS : new data show Cosentyx® improved quality of life over 5 years in two ..
GL
02/16NOVARTIS : new Cosentyx® data confirms robust efficacy and quality of life impro..
GL
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/16NOVARTIS : forms alliance to develop medicines for treating infectious diarrheal..
AQ
02/16NOVARTIS : FDA Approves Another New Generic Form of 40mg Copaxone
AQ
More news
News from SeekingAlpha
02/19Warren Buffett's Berkshire Claims $358 Million Investment In Teva, But That D.. 
02/19Novartis Takes Cosentyx To The Next Level For Patients With Psoriasis 
02/16Novartis to sell U.S. generics unit - Reuters 
02/15FDA issues draft industry guidance for early-stage Alzheimer's disease 
02/14YOUR DAILY PHARMA SCOOP : Akebia Update, Rexahn Data, Concert Commences Enrollme.. 
Financials ($)
Sales 2018 52 000 M
EBIT 2018 13 410 M
Net income 2018 8 890 M
Debt 2018 18 067 M
Yield 2018 3,52%
P/E ratio 2018 21,31
P/E ratio 2019 19,41
EV / Sales 2018 4,67x
EV / Sales 2019 4,46x
Capitalization 225 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 93,2 $
Spread / Average Target 8,5%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
André Wyss President-Novartis Operations
Harry Kirsch Chief Financial Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-3.37%224 785
JOHNSON & JOHNSON-7.19%352 552
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572
AMGEN3.23%133 277